Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $12
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $13 to $12.
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $13 to $12.